drugset

drugset / Trial / NCT00002365

A Study of LXR015-1 in HIV-Infected Patients

NCT00002365 ↗

Phase 1 Completed 30 enrolled LXR Biotechnology

Open-labelTreatment

Summary

To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LXR015-1	Unknown	—	Oral

Indications